Collegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares
November 29 2016 - 7:30AM
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the
underwriters for its public offering of 5,000,000 shares of its
common stock at $16.00 per share have exercised in full their
option to purchase an additional 750,000 shares of common stock at
the public offering price, less the underwriting discounts and
commissions. The closing for the additional purchase of 750,000
shares is expected to take place November 29, 2016, subject to
customary closing conditions. Gross proceeds from the public
offering, including the underwriters’ option to purchase additional
shares are $92 million, excluding underwriters’ discounts and
commissions.
Jefferies LLC and Piper Jaffray & Co. are acting as joint
book-running managers. William Blair & Company, L.L.C.
and Needham & Company, LLC are acting as co-lead managers and
Janney Montgomery Scott LLC is acting as co-manager in this
offering.
The securities described above are being offered by Collegium
pursuant to an effective shelf registration statement (including a
base prospectus) filed with the Securities and Exchange Commission
(“SEC”). Before you invest, you should read the base prospectus in
the registration statement and related prospectus supplement that
Collegium has filed with the SEC for more complete information
about Collegium and this offering. The prospectus supplement and
accompanying base prospectus are available for free by visiting
EDGAR on the SEC’s website located at www.sec.gov. Copies of the
prospectus supplement and accompanying base prospectus, when
available, may also be obtained by contacting: Jefferies LLC, Attn:
Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor,
New York, NY 10022, by telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com; or Piper Jaffray & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, or by telephone at (800) 747-3924 or by
email at prospectus@pjc.com.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on
developing a portfolio of products that incorporate its
patent-protected DETERx technology platform for the treatment of
chronic pain. The DETERx oral drug delivery technology is designed
to provide extended-release delivery, unique abuse-deterrent
properties, and flexible dose administration options.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “should” or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results to differ
materially from the company's current expectations. Management’s
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties
relating to a number of other factors, including statements
regarding the completion, timing and size of the public offering.
These and other risks are described under the heading “Risk
Factors” in our Annual Report on Form 10-K for the year
ended December 31, 2015, as revised and supplemented by our
Quarterly Reports on Form 10-Q filed since the filing of our most
recent Annual Report on Form 10-K and those risks described from
time to time in other reports which we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Investor Contact:
Collegium Pharmaceutical, Inc.
Doug Carlson
Vice President, Corporate Development
dcarlson@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024